- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | ELUTIA INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11. | Elutia Inc.: Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum | 1 | GlobeNewswire (USA) | ||
| 12.11. | Elutia (ELUT) Set to Announce Quarterly Earnings on Thursday | 2 | MarketBeat | ||
| 29.10. | Elutia Inc.: Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024 | 1 | GlobeNewswire (USA) | ||
| 03.10. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| ELUTIA Aktie jetzt für 0€ handeln | |||||
| 18.09. | Elutia Inc.: Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro, Company's Antibiotic-Eluting BioEnvelope for Implantable Devices | 101 | GlobeNewswire (Europe) | EluPro eradicated bacteria commonly associated with cardiac implant-related infections in an established preclinical infection model SILVER SPRING, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Elutia Inc.... ► Artikel lesen | |
| 06.09. | Elutia Inc.: Elutia Celebrates First Year | 1 | GlobeNewswire (USA) | ||
| 05.09. | Elutia Inc.: Elutia Announces First Patient Implant of EluPro, the World's First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators | 73 | GlobeNewswire (Europe) | SILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever... ► Artikel lesen | |
| 03.09. | Elutia Inc.: Elutia to Participate in Upcoming Investor Conferences | 1 | GlobeNewswire (USA) | ||
| 13.08. | ELUTIA INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.08. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.07. | Elutia Inc.: Elutia to Present at the Emerging Growth Conference on Thursday, July 18 | 2 | GlobeNewswire (USA) | ||
| 17.06. | Elutia announces $13.26M direct offering, FDA clearance of EluPro | 1 | Seeking Alpha | ||
| 17.06. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.06. | Elutia Inc.: Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators | 1 | GlobeNewswire (USA) | ||
| 17.06. | Elutia Inc.: Elutia Announces $13.26 Million Registered Direct Offering | 1 | GlobeNewswire (USA) | ||
| 07.06. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.03. | Elutia Inc.: Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM Clearance Decision in First Half of 2024 | 265 | GlobeNewswire (Europe) | SILVER SPRING, Md., March 07, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company") today provided a business update and reported financial results for the fourth quarter... ► Artikel lesen | |
| 10.01. | Elutia Inc.: Elutia Regains Compliance with Nasdaq Listing Requirements | 283 | GlobeNewswire (Europe) | SILVER SPRING, Md., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) today announced that it has regained compliance with Nasdaq's market value of listed securities requirement and majority... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,000 | -13,04 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,361 | -1,63 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,350 | +0,79 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| RECURSION PHARMACEUTICALS | 5,755 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,580 | -3,72 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| ONCOLYTICS BIOTECH | 0,945 | 0,00 % | Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call Transcript | ||
| ARCTURUS THERAPEUTICS | 17,070 | +5,57 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,950 | 0,00 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
| SIGA TECHNOLOGIES | 6,260 | +0,16 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,295 | -0,35 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| VIR BIOTECHNOLOGY | 6,955 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,600 | +1,10 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 17,000 | -2,86 % | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level | ||
| ARVINAS | 25,140 | 0,00 % | Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode | ||
| BIO-PATH | 0,750 | 0,00 % | Bio-Path Holdings, Inc.: Bio-Path Holdings Reports Third Quarter 2024 Financial Results | Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology... ► Artikel lesen |
Das Unternehmen ELUTIA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,140 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELUTIA INC finden Sie auf Wallstreet Online.
